Navigation Links
Isis Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
Date:3/30/2011

CARLSBAD, Calif., March 30, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Needham's 10th Annual Healthcare Conference on Wednesday, April 06, 2011 at 10:40 a.m. ET at the New York Palace Hotel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 EnzymeBioSystems (OTCBB: ... along with the process of evaluating an enzyme ... in fighting tumors. In an effort to evaluate this ... with various contract research organizations to enlist their ... the use of an antitumor natural product called ...
(Date:9/23/2014)... Pa. , Sept. 23, 2014 The Pennsylvania ... drugs Sat., Sept. 27, as part of National Prescription ... no questions asked. Take-Back Day is a ... Enforcement Administration (DEA), aimed at encouraging the public to ... are prone to abuse and theft. From ...
(Date:9/23/2014)... , September 23, 2014 ... related disorders and increasing number of foreign and domestic ... probiotic in India   ... of the most high growth potential markets worldwide due ... consumers especially among the youth, changing food consumption patterns, ...
Breaking Medicine Technology:EnzymeBioSystems Announces Progress with an Enzyme Compound 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3
... LAKE, N.J., Nov. 9 Par Pharmaceutical Companies, Inc. ... extended the expiration date and increased the purchase price ... in which Par is offering to purchase, for cash, ... approximately 82.7%, of its outstanding 2.875% Senior Subordinated Convertible ...
... , NEW YORK, Nov. 9 MISSION Skincare®, the ... soccer professional Mia Hamm, and other world class athletes, ... beauty aisle of more than 5,000 CVS/pharmacy locations across ... face, body and sun care products, MISSION and CVS/pharmacy ...
Cached Medicine Technology:Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 2Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 3
(Date:9/23/2014)... A new analysis of published studies found that ... cancer versus benign disease in regions where infections ... of lung lesions suspicious for cancer could lead ... additional potential complications and mortality. , Histoplasmosis ... that are often concentrated in bird droppings and ...
(Date:9/23/2014)... California, Davis, and Academia Sinica, the preeminent academic ... entered into a collaborative agreement to develop a ... cutting-edge research with opportunities to translate innovative technologies ... The agreement was signed Sept.12 in Taipei by ... Davis and President Chi-Huey Wong of Academia Sinica. ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows ... how it can be treated. , A medically retired ... 2006. His platoon sustained multiple attacks resulting in five ... with combat-related PTSD and honorably discharged from the Army. ... had distanced myself from my friends and family,” recalled ...
(Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
Breaking Medicine News(10 mins):Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3
... heart expert calls it ,second-line, medication , , FRIDAY, ... the highly promoted cholesterol-lowering drug Vytorin continued Friday ... the medication,s effectiveness, but only after final trial ... this month when preliminary results of the so-called ...
... WellPoint, Inc. (NYSE:,WLP) announced today that senior ... Conference on January 30, 2008. The presentation is,expected ... All interested parties are invited to listen ... http://www.wellpoint.com and selecting the "Investor,Info" link. Following ...
... Ronit Calderon-Margalit, MD, MPH, Marianna Mazar, MD and Zvi ... Jewish and Arab diabetes sufferers who were admitted to ... whether differences existed between the two groups and, if ... health insurance coverage. The researchers found significant differences. As ...
... Jan. 25 Pizza, nachos, dip and wings ... also have one thing in common:,they can all ... counter heartburn medicine based on dollar sales, is ... tasty heartburn-friendly,alternatives., , Listen to this report ...
... Belgium have significantly advanced the discovery of a pancreatic ... beta cells. If the finding made in mice holds ... obvious target for therapeutic regeneration of beta cells in ... of the research journal Cell, a publication of Cell ...
... The North Carolina,Association of Educators (NCAE) will launch a ... at increasing awareness about good eating,habits and physical fitness ... from NCAE," is slated to run in,newspapers across North ... NCAE logo -- star in an ad campaign to,encourage ...
Cached Medicine News:Health News:FDA Will Wait for Trial Results on Vytorin 2Health News:FDA Will Wait for Trial Results on Vytorin 3Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:Elusive pancreatic progenitor cells found in mice 2Health News:NCAE Encourages Minority Youth and Their Families to 'Go-for' Health and Fitness 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: